Redeye retains its positive stance towards Hanza despite a softer Q2 report than expected regarding ...
- Q2: Adj. EBITDA of NOK 1m - New targets more achievable — sales +22% in '25e vs '23 - Customers re...
Redeye provides an initial take on Sedana Medical’s Q2 results, and we will return with a more in-de...
Redeye notes Q2 sales spot on our estimates, but an EBIT far from our expectations (though heavily i...
Redeye provides its initial take on Mentice’s Q2 2024 report, which exceeded our estimates.
- Q2 EBITDA beating by 9-13% on product mix, scale and cost focus - Guidance hiked despite continued...
Redeye sees a mixed quarter from Hanza. While sales and adjusted EBITA were somewhat below our expec...
Redeye returns with an updated take following a solid Q2 report from Stille, showing very minor devi...
- Weak Q2, -6% on sales and -25% on adj. EBIT vs ABGSCe - FCF generation held back by R&D capitalisa...
Beijer Alma levererar stabilt kvartal med både förvärvsdriven och organisk tillväxt samt en ordering...
Både omsättning och resultat stärktes under kvartalet, vilket förstärker vår syn om en positiv resul...
Fastighetsbolaget Trianons driftnetto ökade till 134,0 (130,6) miljoner kronor under det andra kvart...
Finnair’s Q2 EBIT missed our estimate due to slight negative surprises in revenue and costs.
- 3% organic growth to accelerate to 18-16% H2'24e - 22% adj.
Redeye offers an update on Advenica following the company's Q2 report.
